Hospital.Help

Brussels The European Medicines Agency (EMA) has spoken out against an extension of the indication for semaglutide to prevent cardiovascular events, but recommends including additional information in the product information. The Committee for Medicinal Products for Human Use (CHMP) recently made the recommendation. The CHMP was of the opinion that this application was already approved by the…